Abstract
The reauthorization of the Prescription Drug User Fee Act (PDUFA)—a system where drug companies pay fees to FDA to support its process for reviewing applications for new drugs and biologicals—is “an extremely important step” for the agency, said Commissioner Andrew C. von Eschenbach.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.